Answers are grounded in this paper and cite their sources.
Skin and soft tissue infections (SSTIs) have increasing prevalence in clinical practice. The emergence of resistant pathogens and especially methicillin-resistant Staphylococcus aureus (MRSA) has led to an increase in the number of hospitalizations due to SSTIs. Daptomycin has been shown to achieve good concentrations in skin and soft tissues and is effective and safe for the treatment of SSTIs. In this review, I summarize the scientific evidence regarding the role of daptomycin in therapy of SSTIs, comparing daptomycin with other antimicrobial agents.
No takes yet. Share an insight, caveat, or question.
Theodoros Kelesidis (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: